I am fascinating by the work @jbuell01 is doing at $INKT. Although very early stage and essentially pre-revenue, at a market cap of just $51M $INKT has appealing odds of becoming global immune system platform. iNKTs work where everything else fails. https://t.co/zJP1YQ6SUi
View on X ↗